SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Medistem, Inc. (Pink Sheets:MEDS), today announced that its President and CSO, Thomas Ichim, Ph.D., will present at the Aegis Capital 2013 Healthcare Conference being held at The Encore at Wynn Las Vegas, September 25-28. The presentation is scheduled for Friday, September 27th at 8:30 a.m. (PDT).
The company will discuss its progress in development of ERC-124, its stem cell product. The company believes ERC-124 possesses the 5 characteristics needed for development of a successful stem cell therapy, specifically:
a) Safety
b) Efficacy
c) Easily accessible, economic and scalable
d) Universal donor
e) Strong intellectual property
Currently ERC-124 is in development for congestive heart failure, critical limb ischemia, and Type 1 diabetes. ERC-124 was cleared by the FDA for a Phase I/II clinical trial in critical limb ischemia. Management will be available for one-on-one meetings throughout the conference. To arrange a meeting please contact John Salvador, Chief Operating Officer at 626 644 6092.
About Medistem, Inc.
Medistem, Inc., is developing ERC-124, a universal stem cell product derived from the endometrium. ERC-124 possesses specialized abilities to stimulate new blood vessel formation and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERC-124 has been cleared by the FDA to begin a CLI clinical trial in the United States. In January 2012, the Company announced the initiation of its RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy) a double blind, placebo controlled, clinical trial. This trial is being conducted at the Bakulev Scientific Center for Cardiovascular Surgery, Moscow, Russia. The trial is a 60 patient double blind placebo controlled study evaluating safety and efficacy of ERC-124 in end stage CHF patients.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem, Inc. These can be identified by the use of forward‐looking words, such as "believes", "expects", "may", "intends", "anticipates", "plans", "estimates", or any other analogous or similar expressions intended to identify forward‐looking statements. These forward‐looking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
John P. Salvador 626.644.6092
